Talmadge E. King Jr, MD

Dean-SOM/VC-Medical Affairs

Dr. Talmadge E. King, Jr. was named dean of the UCSF School of Medicine and vice chancellor for medical affairs in May of 2015. He began his career at UCSF in 1997 as chief of Medical Services at Priscilla Chan and Mark Zuckerberg San Francisco General Hospital and Trauma Center. From 2006 to 2015, he served as chair of the UCSF Department of Medicine, the largest department in the school, with approximately 29 percent of the school's full-time faculty.

A physician-scientist, King’s research has focused on inflammatory and immunologic lung injury. He is best known for his pioneering work in the management of the interstitial pneumonias, a scarring process that often leads to death. His bibliography comprises more than 300 publications and he has co-edited eight books, including the acclaimed reference book, "Interstitial Lung Disease," now in its fifth edition.

King graduated from Gustavus Adolphus College and earned his medical degree at Harvard Medical School, followed by a residency at Emory University Affiliated Hospitals in Atlanta, Ga. and a pulmonary fellowship at the University of Colorado Health Sciences Center in Denver.

He is a member of the Institute of Medicine of the National Academy of Sciences, American Academy of Arts and Sciences, Association of American Physicians, American Clinical and Climatological Association and the Fleischner Society. He is a master of the American College of Physicians and fellow of the American College of Chest Physicians. He won the 2007 Trudeau Medal, the highest honor of the American Thoracic Society.

Education
2018 - Diversity, Equity, and Inclusion Champion Training, University of California
Fellowship, 1979 - Pulmonary/Critical Care, University of Colorado Medical Cente
Residency, 1977 - Internal Medicine, Emory University
M.D., 1974 - School of Medicine, Harvard University
Honors and Awards
  • 2016 APM Robert H. Williams, MD, Distinguished Chair of Medicine Award, Association of Professors of Medicine (APM), 2016
  • Breathing for Life Award, Foundation of the American Thoracic Society, 2012
  • Sesquicentennial Award, Gustavus Adolphus College, 2012
  • Fellow, American Academy of Arts and Sciences, 2011
  • Master, American College of Physicians, 2010
  • Alumni Citation, Gustavus Alumni Association, Gustavus Adolphus College, 2008
  • Trudeau Medal, American Thoracic Society, 2007
  • Member, Institute of Medicine, National Academy of Sciences, 2004
  • PAR Excellence Award, Public Advisory Roundtable of the American Thoracic Society, 2003
  • Member, Association of American Physicians, 1998
  • Elected honorary member, California Thoracic Society, 1998
  • Member. Colorado Pulmonary Hall of Fame, Colorado Thoracic Society, American Lung Association of Colorado, 1998
  • Member, The Fleischner Society, 1997
  • Member, Western Association of Physicians, 1993
  • James J. Waring Award For Outstanding Leadership in the Treatment of Lung Disease, American Lung Association of Colorado, 1992
  • Fellow, American College of Physicians, 1986
  • Fellow, American College of Chest Physicians, 1984
  • First Decade Award for Early Achievement, Alumni Association, Gustavus Adolphus College, 1980
  • Guild of St. Ansger Honor Society, Gustavus Adolphus College, 1970
Websites
Publications
  1. Crotty Alexander LE, Ware LB, Calfee CS, Callahan SJ, Eissenberg T, Farver C, Goniewicz ML, Jaspers I, Kheradmand F, King TE, Meyer NJ, Mikheev V, Shields PG, Shihadeh A, Strongin R, Tarran R. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda. 2020. PMID: 32243764


  2. Lucey CR, Navarro R, King TE. Lessons From an Educational Never Event. Volume 177 of Issue 10. 2017. PMID: 28846754


  3. Morisset J, Vittinghoff E, Elicker BM, Hu X, Le S, Ryu JH, Jones KD, Haemel A, Golden JA, Boin F, Ley B, Wolters PJ, King TE, Collard HR, Lee JS. Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model. Volume 152 of Issue 5. 2017. PMID: 28629914


  4. Morisset J, Vittinghoff E, Lee BY, Tonelli R, Hu X, Elicker BM, Ryu JH, Jones KD, Cerri S, Manfredi A, Sebastiani M, Gross AJ, Ley B, Wolters PJ, King TE, Kim DS, Collard HR, Lee JS. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. Volume 127. 2017. PMID: 28502419


  5. Brownell R, Moua T, Henry TS, Elicker BM, White D, Vittinghoff E, Jones KD, Urisman A, Aravena C, Johannson KA, Golden JA, King TE, Wolters PJ, Collard HR, Ley B. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Volume 72 of Issue 5. 2017. PMID: 28082530


  6. Sehgal NL, Neeman N, King TE. Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process. Volume 92 of Issue 1. 2017. PMID: 27119329


  7. Johannson KA, Elicker BM, Vittinghoff E, Assayag D, de Boer K, Golden JA, Jones KD, King TE, Koth LL, Lee JS, Ley B, Wolters PJ, Collard HR. A diagnostic model for chronic hypersensitivity pneumonitis. Volume 71 of Issue 10. 2016. PMID: 27245779


  8. Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Volume 71 of Issue 5. 2016. PMID: 26968970


  9. Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. Volume 3 of Issue 1. 2016. PMID: 26835133


  10. Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Volume 47 of Issue 1. 2015. PMID: 26647432


  11. Sverzellati N, Lynch DA, Hansell DM, Johkoh T, King TE, Travis WD. American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002. Volume 35 of Issue 7. 2015. PMID: 26452110


  12. Assayag D, Kim EJ, Elicker BM, Jones KD, Golden JA, King TE, Koth LL, Shum AK, Wolters PJ, Collard HR, Lee JS. Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria. Volume 109 of Issue 10. 2015. PMID: 26303338


  13. Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Volume 148 of Issue 1. 2015. PMID: 25856121


  14. Assayag D, Vittinghoff E, Ryerson CJ, Cocconcelli E, Tonelli R, Hu X, Elicker BM, Golden JA, Jones KD, King TE, Koth LL, Lee JS, Ley B, Shum AK, Wolters PJ, Ryu JH, Collard HR. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Volume 109 of Issue 8. 2015. PMID: 26140806


  15. Hansell DM, Goldin JG, King TE, Lynch DA, Richeldi L, Wells AU. CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. Volume 3 of Issue 6. 2015. PMID: 25975761


  16. Nathan SD, du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Volume 109 of Issue 7. 2015. PMID: 25956020


  17. Collard HR, Bradford WZ, Cottin V, Flaherty KR, King TE, Koch GG, Kolb M, Martinez FJ, Montgomery B, Raghu G, Richeldi L, Rose D, Wells AU, Brown KK. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. Volume 46 of Issue 1. 2015. PMID: 25900377


  18. Durheim MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE, Palmer SM, Raghu G, Snyder LD, Anstrom KJ, Martinez FJ. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Volume 3 of Issue 5. 2015. PMID: 25890798


  19. Moodley Y, Corte T, Richeldi L, King TE. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. Volume 20 of Issue 3. 2015. PMID: 25727967


  20. Costabel U, Albera C, Bradford WZ, Hormel P, King TE, Noble PW, Sahn SA, Valeyre D, du Bois RM. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Volume 31 of Issue 3. 2014. PMID: 25363219


  21. King TE, Noble PW, Bradford WZ. Treatments for idiopathic pulmonary fibrosis. Volume 371 of Issue 8. 2014. PMID: 25147884


  22. Flaherty KR, Fell C, Aubry MC, Brown K, Colby T, Costabel U, Franks TJ, Gross BH, Hansell DM, Kazerooni E, Kim DS, King TE, Kitachi M, Lynch D, Myers J, Nagai S, Nicholson AG, Poletti V, Raghu G, Selman M, Toews G, Travis W, Wells AU, Vassallo R, Martinez FJ. Smoking-related idiopathic interstitial pneumonia. Volume 44 of Issue 3. 2014. PMID: 25063244


  23. Ley B, Elicker BM, Hartman TE, Ryerson CJ, Vittinghoff E, Ryu JH, Lee JS, Jones KD, Richeldi L, King TE, Collard HR. Idiopathic pulmonary fibrosis: CT and risk of death. Volume 273 of Issue 2. 2014. PMID: 24927326


  24. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Volume 370 of Issue 22. 2014. PMID: 24836312


  25. Valeyre D, Albera C, Bradford WZ, Costabel U, King TE, Leff JA, Noble PW, Sahn SA, du Bois RM. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Volume 19 of Issue 5. 2014. PMID: 24836849


  26. . Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. Volume 370 of Issue 22. 2014. PMID: 24836309


  27. King TE, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Volume 189 of Issue 7. 2014. PMID: 24476390


  28. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE, Collard HR. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Volume 145 of Issue 4. 2014. PMID: 24114524


  29. Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, Bradford W, Brown KK, Chapman HA, Collard HR, Cosgrove GP, Deterding R, Doyle R, Flaherty KR, Garcia CK, Hagood JS, Henke CA, Herzog E, Hogaboam CM, Horowitz JC, King TE, Loyd JE, Lawson WE, Marsh CB, Noble PW, Noth I, Sheppard D, Olsson J, Ortiz LA, O'Riordan TG, Oury TD, Raghu G, Roman J, Sime PJ, Sisson TH, Tschumperlin D, Violette SM, Weaver TE, Wells RG, White ES, Kaminski N, Martinez FJ, Wynn TA, Thannickal VJ, Eu JP. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Volume 189 of Issue 2. 2014. PMID: 24160862


  30. Assayag D, Lee JS, King TE. Rheumatoid arthritis associated interstitial lung disease: a review. Volume 74 of Issue 2. 2014. PMID: 24736263


  31. Assayag D, Lubin M, Lee JS, King TE, Collard HR, Ryerson CJ. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Volume 19 of Issue 4. 2013. PMID: 24372981


  32. Swigris JJ, Streiner DL, Brown KK, Belkin A, Green KE, Wamboldt FS. Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. Volume 108 of Issue 1. 2013. PMID: 24388667


  33. du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Volume 43 of Issue 5. 2013. PMID: 24311766


  34. Assayag D, Elicker BM, Urbania TH, Colby TV, Kang BH, Ryu JH, King TE, Collard HR, Kim DS, Lee JS. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Volume 270 of Issue 2. 2013. PMID: 24126367


  35. Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Volume 188 of Issue 6. 2013. PMID: 24032382


  36. Mooney JJ, Elicker BM, Urbania TH, Agarwal MR, Ryerson CJ, Nguyen MLT, Woodruff PG, Jones KD, Collard HR, King TE, Koth LL. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Volume 144 of Issue 2. 2013. PMID: 23392130


  37. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Volume 14. 2013. PMID: 23848435


  38. Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, Jones KD, King TE, Ryu J, Collard HR. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Volume 144 of Issue 1. 2013. PMID: 23370641


  39. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Volume 1 of Issue 5. 2013. PMID: 24429201


  40. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. Volume 187 of Issue 11. 2013. PMID: 23725623


  41. Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Volume 143 of Issue 6. 2013. PMID: 23732584


  42. Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE, Wolters PJ, Collard HR. Prevalence and prognosis of unclassifiable interstitial lung disease. Volume 42 of Issue 3. 2012. PMID: 23222877


  43. Lee JS, Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, Shum AK, Wolters PJ, Cerri S, Richeldi L, Jones KD, King TE, Collard HR. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Volume 107 of Issue 2. 2012. PMID: 23186614


  44. Selman M, Pardo A, King TE. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Volume 186 of Issue 4. 2012. PMID: 22679012


  45. . Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. Volume 366 of Issue 21. 2012. PMID: 22607134


  46. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Volume 156 of Issue 10. 2012. PMID: 22586007


  47. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Volume 186 of Issue 1. 2012. PMID: 22561965


  48. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Volume 185 of Issue 10. 2012. PMID: 22505745


  49. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE, Ryu JH, Collard HR. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Volume 67 of Issue 5. 2012. PMID: 22426899


  50. King TE, Collard HR, Richeldi L. Interstitial lung diseases. Preface. Volume 33 of Issue 1. 2012. PMID: 22365255


  51. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Volume 184 of Issue 12. 2011. PMID: 21940789


  52. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Volume 184 of Issue 4. 2011. PMID: 21616999


  53. King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Volume 378 of Issue 9807. 2011. PMID: 21719092


  54. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE, Collard HR. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Volume 184 of Issue 12. 2011. PMID: 21700909


  55. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Volume 377 of Issue 9779. 2011. PMID: 21571362


  56. King TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Volume 184 of Issue 1. 2011. PMID: 21474646


  57. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Volume 183 of Issue 6. 2011. PMID: 21471066


  58. King TE. Smoking and subclinical interstitial lung disease. Volume 364 of Issue 10. 2011. PMID: 21388315


  59. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Volume 183 of Issue 9. 2010. PMID: 21131468


  60. Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Volume 183 of Issue 4. 2010. PMID: 20935110


  61. Castriotta RJ, Eldadah BA, Foster WM, Halter JB, Hazzard WR, Kiley JP, King TE, Horne FM, Nayfield SG, Reynolds HY, Schmader KE, Toews GB, High KP. Workshop on idiopathic pulmonary fibrosis in older adults. Volume 138 of Issue 3. 2010. PMID: 20822991


  62. Arjomandi M, Seward J, Gotway MB, Nishimura S, Fulton GP, Thundiyil J, King TE, Harber P, Balmes JR. Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility. Volume 52 of Issue 6. 2010. PMID: 20523233


  63. Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, Ishizaka A, Jones KD, King TE, Matthay MA, Kim DS. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Volume 299 of Issue 1. 2010. PMID: 20418386


  64. Lee JS, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM, Golden JA, King TE. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Volume 123 of Issue 4. 2010. PMID: 20362747


  65. Kinder BW, Shariat C, Collard HR, Koth LL, Wolters PJ, Golden JA, Panos RJ, King TE. Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. Volume 188 of Issue 2. 2010. PMID: 20069430


  66. Levinson W, King TE, Goldman L, Goroll AH, Kessler B. Clinical decisions. American Board of Internal Medicine maintenance of certification program. Volume 362 of Issue 10. 2010. PMID: 20220192


  67. Swigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, Brown KK. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Volume 65 of Issue 2. 2009. PMID: 19996335


  68. Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, Wamboldt FS. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Volume 104 of Issue 2. 2009. PMID: 19815403


  69. Buckley JD, Addrizzo-Harris DJ, Clay AS, Curtis JR, Kotloff RM, Lorin SM, Murin S, Sessler CN, Rogers PL, Rosen MJ, Spevetz A, King TE, Malhotra A, Parsons PE. Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine. Volume 180 of Issue 4. 2009. PMID: 19661252


  70. King TE, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Volume 374 of Issue 9685. 2009. PMID: 19570573


  71. Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, King TE. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Volume 135 of Issue 6. 2009. PMID: 19255294


  72. King TE. Bosentan for idiopathic pulmonary fibrosis. Volume 9 of Issue 11. 2008. PMID: 18951296


  73. Kinder BW, King TE. Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease. Volume 177 of Issue 11. 2008. PMID: 18487622


  74. Travis WD, Hunninghake G, King TE, Lynch DA, Colby TV, Galvin JR, Brown KK, Chung MP, Cordier JF, du Bois RM, Flaherty KR, Franks TJ, Hansell DM, Hartman TE, Kazerooni EA, Kim DS, Kitaichi M, Koyama T, Martinez FJ, Nagai S, Midthun DE, Müller NL, Nicholson AG, Raghu G, Selman M, Wells A. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Volume 177 of Issue 12. 2008. PMID: 18388353


  75. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Volume 133 of Issue 1. 2007. PMID: 18071016


  76. du Bois R, King TE. Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate. Volume 62 of Issue 11. 2007. PMID: 17965079


  77. King TE, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Volume 177 of Issue 1. 2007. PMID: 17901413


  78. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE, Golden JA. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Volume 102 of Issue 1. 2007. PMID: 17822892


  79. Kinder BW, Freemer MM, King TE, Lum RF, Nititham J, Taylor K, Edberg JC, Bridges SL, Criswell LA. Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. Volume 56 of Issue 8. 2007. PMID: 17665457


  80. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Müller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ. Acute exacerbations of idiopathic pulmonary fibrosis. Volume 176 of Issue 7. 2007. PMID: 17585107


  81. Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, Jones KD, King TE. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Volume 176 of Issue 7. 2007. PMID: 17556720


  82. Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, Gaxiola M, Pérez-Padilla R, Navarro C, Richards T, Dauber J, King TE, Pardo A, Kaminski N. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. Volume 2 of Issue 5. 2007. PMID: 17534432


  83. Collard HR, Loyd JE, King TE, Lancaster LH. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Volume 101 of Issue 9. 2007. PMID: 17509853


  84. Portnoy J, Veraldi KL, Schwarz MI, Cool CD, Curran-Everett D, Cherniack RM, King TE, Brown KK. Respiratory bronchiolitis-interstitial lung disease: long-term outcome. Volume 131 of Issue 3. 2007. PMID: 17356078


  85. Calfee CS, Shah SJ, Wolters PJ, Saint S, King TE. Clinical problem-solving. Anchors away. Volume 356 of Issue 5. 2007. PMID: 17267911


  86. Flaherty KR, Andrei AC, King TE, Raghu G, Colby TV, Wells A, Bassily N, Brown K, du Bois R, Flint A, Gay SE, Gross BH, Kazerooni EA, Knapp R, Louvar E, Lynch D, Nicholson AG, Quick J, Thannickal VJ, Travis WD, Vyskocil J, Wadenstorer FA, Wilt J, Toews GB, Murray S, Martinez FJ. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Volume 175 of Issue 10. 2007. PMID: 17255566


  87. Kinder BW, Collard HR, King TE. Anticoagulant therapy and idiopathic pulmonary fibrosis. Volume 130 of Issue 1. 2006. PMID: 16840421


  88. Kim DS, Collard HR, King TE. Classification and natural history of the idiopathic interstitial pneumonias. Volume 3 of Issue 4. 2006. PMID: 16738191


  89. Walter N, Collard HR, King TE. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Volume 3 of Issue 4. 2006. PMID: 16738197


  90. Perez RL, Kimani AP, King TE, Aguayo SM, Roman J. Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis. Volume 74 of Issue 3. 2006. PMID: 16534178


  91. Wesson DE, King TE, Todd RF, Torres EA, Hellmann DB, Flack JM, Dubose TD, Schuster VL. Achieving diversity in academic internal medicine: recommendations for leaders. Volume 119 of Issue 1. 2006. PMID: 16431199


  92. Shah NR, Noble P, Jackson RM, King TE, Nathan SD, Padilla M, Raghu G, Rhodes MB, Schwarz M, Tino G, Dubois RW. A critical assessment of treatment options for idiopathic pulmonary fibrosis. Volume 22 of Issue 3. 2005. PMID: 16315778


  93. Girod CE, King TE. COPD: a dust-induced disease? Volume 128 of Issue 4. 2005. PMID: 16236986


  94. Lynch DA, Travis WD, Müller NL, Galvin JR, Hansell DM, Grenier PA, King TE. Idiopathic interstitial pneumonias: CT features. Volume 236 of Issue 1. 2005. PMID: 15987960


  95. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK. The clinical course of patients with idiopathic pulmonary fibrosis. Volume 142 of Issue 12 Pt 1. 2005. PMID: 15968010


  96. Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE, Bradford WZ, Schwartz DA, Richard Webb W. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Volume 172 of Issue 4. 2005. PMID: 15894598


  97. King TE. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Volume 172 of Issue 3. 2005. PMID: 15879420


  98. King TE, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Volume 127 of Issue 1. 2005. PMID: 15653980


  99. King TE, Wheeler MB. Inequality in health care: unjust, inhumane, and unattended! Volume 141 of Issue 10. 2004. PMID: 15545683


  100. Flaherty KR, King TE, Raghu G, Lynch JP, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Volume 170 of Issue 8. 2004. PMID: 15256390


  101. Collard HR, Ryu JH, Douglas WW, Schwarz MI, Curran-Everett D, King TE, Brown KK. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Volume 125 of Issue 6. 2004. PMID: 15189938


  102. Vourlekis JS, Schwarz MI, Cherniack RM, Curran-Everett D, Cool CD, Tuder RM, King TE, Brown KK. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Volume 116 of Issue 10. 2004. PMID: 15121492


  103. King TE, Dickinson TA, DuBose TD, Flack JM, Hellmann DB, Pamies RJ, Todd RF, Torres EA, Wesson DE. The case for diversity in academic internal medicine. Volume 116 of Issue 4. 2004. PMID: 14969662


  104. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. Volume 350 of Issue 2. 2004. PMID: 14711911


  105. Hunninghake GW, Lynch DA, Galvin JR, Gross BH, Müller N, Schwartz DA, King TE, Lynch JP, Hegele R, Waldron J, Colby TV, Hogg JC. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Volume 124 of Issue 4. 2003. PMID: 14555549


  106. Morris DG, Jasmer RM, Huang L, Gotway MB, Nishimura S, King TE. Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence. Volume 124 of Issue 3. 2003. PMID: 12970019


  107. Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Volume 168 of Issue 5. 2003. PMID: 12773325


  108. Collard HR, King TE. Demystifying idiopathic interstitial pneumonia. Volume 163 of Issue 1. 2003. PMID: 12523913


  109. Inoue Y, King TE, Barker E, Daniloff E, Newman LS. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Volume 166 of Issue 5. 2002. PMID: 12204879


  110. Crystal RG, Bitterman PB, Mossman B, Schwarz MI, Sheppard D, Almasy L, Chapman HA, Friedman SL, King TE, Leinwand LA, Liotta L, Martin GR, Schwartz DA, Schultz GS, Wagner CR, Musson RA. Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Volume 166 of Issue 2. 2002. PMID: 12119236


  111. King TE. Nonspecific interstitial pneumonia and systemic sclerosis. Volume 165 of Issue 12. 2002. PMID: 12070054


  112. King TE. Racial disparities in clinical trials. Volume 346 of Issue 18. 2002. PMID: 11986416


  113. Vourlekis JS, Schwarz MI, Cool CD, Tuder RM, King TE, Brown KK. Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis. Volume 112 of Issue 6. 2002. PMID: 11959061


  114. Park JS, Brown KK, Tuder RM, Hale VA, King TE, Lynch DA. Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation. Volume 26 of Issue 1. 2002. PMID: 11801899